drugset / Trial / NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Timeline
- Start
- 2025-05-06
- Primary completion
- 2027-12-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azercabtagene zapreleucel | Unknown | — | Intravenous |